838 results on '"Arock, Michel"'
Search Results
2. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
3. Nouveaux critères diagnostiques des mastocytoses : des progrès mais encore des interrogations
4. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
5. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
6. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
7. Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes
8. World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future Perspectives
9. KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies
10. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
11. Human C1q Tumor Necrosis Factor 8 (CTRP8) defines a novel tryptase+ mast cell subpopulation in the prostate cancer microenvironment
12. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
13. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
14. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis
15. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
16. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
17. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
18. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
19. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
20. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
21. Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders
22. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.
23. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
24. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
25. KIT and Other Mutations in Mastocytosis
26. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
27. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
28. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
29. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity
30. SR‐BI regulates the synergistic mast cell response by modulating the plasma membrane‐associated cholesterol pool.
31. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
32. Case Report: A family history of peanut allergy and hereditary alpha-tryptasemia
33. Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils
34. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
35. Involvement of an IgE/Mast cell/B cell amplification loop in abdominal aortic aneurysm progression
36. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
37. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry
38. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS
39. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
40. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives
41. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
42. KIT and Other Mutations in Mastocytosis
43. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
44. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
45. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT
46. Identification of a leukemia-initiating stem cell in human mast cell leukemia
47. Cladribine improves cutaneous manifestations, Dermatology Life Quality Index, and Mastocytosis Quality of Life of patients with mastocytosis
48. Is lirentelimab the ‘magic bullet’ to fight pathological mast-cell activation in systemic mastocytosis?
49. Tumor necrosis factor α promotes clonal dominance of KITD816V+cells in mastocytosis: role of survivin and impact on prognosis
50. Immunomodulatory role of Interleukin-33 in large vessel vasculitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.